Clinical and radiological improvement of cavitary Mycobacteroides abscessus disease in cystic fibrosis following initiation of elexacaftor/tezacaftor/ivacaftor.
J Cyst Fibros
; 23(5): 1024-1026, 2024 Sep.
Article
em En
| MEDLINE
| ID: mdl-38777631
ABSTRACT
Elexacaftor/tezacaftor/ivacaftor (ETI) is a CFTR modulator therapy that has dramatically improved the health outcomes for many people with cystic fibrosis (pwCF). There is increasing interest in the role of CFTR modulators in the prevention and treatment of respiratory infections in pwCF. A male patient with F508del homozygous cystic fibrosis developed cavitary Mycobacteroides abscessus subspecies bolletii & massiliense respiratory infection. Antimycobacterial treatment was not given as, in discussion with the patient's family, it was deemed unlikely that the intensive regimen would be tolerated by the patient on account of his autism spectrum disorder. Following initiation of ETI, there was a rapid clinical and radiological improvement in this patient's cavitary lung disease. This case adds to the evidence base that suggests CFTR modulators, particularly ETI, may restore innate immune function leading to improved outcomes for pulmonary infection in pwCF.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Piridinas
/
Quinolonas
/
Fibrose Cística
/
Benzodioxóis
/
Aminofenóis
/
Indóis
/
Infecções por Mycobacterium não Tuberculosas
Limite:
Adult
/
Humans
/
Male
Idioma:
En
Revista:
J Cyst Fibros
Ano de publicação:
2024
Tipo de documento:
Article